Venus Remedies Secures Major Dual Tender From UNICEF And PAHO

Three months after receiving the prestigious Good Manufacturing Practices (GMP) certification from the United Nations International Children’s Emergency Fund (UNICEF), Venus Remedies has secured a tender from UNICEF to supply ceftriaxone (1gm) in dry powder form, a beta-lactam antibiotic.

Ceftriaxone dry powder is a key product in Venus Remedies’ broad antibiotic range and is crucial worldwide due to its broad-spectrum efficacy in treating severe bacterial infections. The global market for ceftriaxone was valued at USD 1.7 billion in 2021 and is projected to grow at a CAGR of 2.9 percent from 2022 to 2031, reaching over USD 2.2 billion by 2031.

Additionally, Venus Remedies has won an oncology tender from the WHO-supported Pan American Health Organisation (PAHO), tasking the company with supplying a variety of essential oncology drugs including bleomycin, carboplatin, cisplatin, cytarabine, doxorubicin, irinotecan, methotrexate, and vincristine.

India, having exported pharmaceuticals worth approximately USD 16 billion in the financial year 2023-2024, stands as the largest global supplier of generic drugs. Indian pharmaceuticals account for 20 percent of the global generic drug market by volume. Venus Remedies is significantly contributing to this export sector, bolstering India’s growing impact, especially in the global oncology market.